Please login to the form below

Not currently logged in
Email:
Password:

NDA Group appoints Bill Griffiths as general manager, UK

He also becomes vice president of the consultancy's advisory board

NDA Group has appointed Bill Griffiths as general manager of its UK team and vice president of its advisory board.

Based in Leatherhead, Surrey, Griffiths will be responsible for managing the European regulatory affairs and patient safety consultancy's business in the UK with effect from 1 March.

He will also be responsible for managing the development, operations and strategy of the firm's advisory board, working closely with the board's regulatory director Steffen Thristrup and NDA Group's scientific director Markku Toivonen.

Griffiths brings nearly 30 years of pharmaceutical experience to the role, having held senior positions at GlaxoSmithKline, Pfizer and Solvay Pharmaceuticals.

He joins the consultancy from Abbott Pharmaceuticals, where he served in Basel as its divisional vice president of global regulatory affairs.

In that role, Griffiths oversaw the regulatory function of the Europe, Latin America, Asia Pacific, India and Japan teams, the company's labeling and advertising promotion, policy and intelligence and quality systems teams as well as a specialist influenza vaccines unit.

Johan Stromquist, NDA Group's chief executive officer, said: “The UK consulting team is NDA's largest team and one of the most important business units for NDA. Identifying an individual with the right background, skillset and experience to support our experienced team and client base has been a challenge.

“I am therefore delighted to bring Bill on board. He brings a fantastic background with both strong pharmaceutical expertise, coupled with outstanding team management - key criteria for driving our UK operations forward.”

24th February 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics